EC Number   |
General Information |
Reference |
|---|
    1.1.1.44 | drug target |
abrogating 6-phosphogluconate dehydrogenase Y481 phosphorylation (pY481) dramatically attenuates epidermal growth factor receptor(EGF) promotes glioma cell proliferation, tumor growth and resistance to ionizing radiation. 6PGD pY481 is associated with Fyn expression, the malignancy and prognosis of human glioblastoma. Critical role of Fyn-dependent 6-phosphogluconate dehydrogenase (6PGD) phosphorylation in EGF-promoted tumor growth and radiation resistance |
761976 |
| 1.1.1.44 | drug target |
blockade of 6-phosphogluconate dehydrogenase reprograms CD8+ T cell metabolism to support superior effector function with higher tumoricidal activity. This metabolic checkpoint represents a key therapeutic target for cancer immunotherapies |
760842 |
| 1.1.1.44 | drug target |
Plasmodium falciparum 6-phosphogluconate dehydrogenase is an antimalarial drug target |
761698 |
| 1.1.1.44 | drug target |
targeting 6-phosphogluconate dehydrogenase (6PGD) and NADPH production is sufficient to block growth of acute myeloid leukemia cell lines resistant to the chemotherapeutics daunorubicin and cytarabine. Stromal cell-mediated resistance to targeted inhibition of oncogenic FLT3 kinase activity by quizartinib is circumvented by 6PGD knockdown |
762077 |
| 1.1.1.44 | drug target |
the enzyme (6PGD) is a putative therapeutic drug target in breast cancer treatment. Targeting 6PGD not only reduces cell proliferation through cell cycle arrest and apoptosis induction but also activates p53 and decreases the stem cell-like characteristics of breast cancer cells. Inhibition of 6PGD alters the stem cell characteristics and mammosphere formation capabilities of MCF-7 cells, opening new avenues to prevent cancer recurrance after surgery or chemotherapy. Inhibition of 6PGD via chemical inhibitor 1-hydroxy-8-methoxy-anthraquinone results in an induction of senescence, which, together with the cell cycle arrest and apoptosis induction, might be orchestrated by p53 activation |
760664 |
| 1.1.1.44 | drug target |
the enzyme is an attractive antimalarial drug target due to its central role in metabolism |
761698 |
| 1.1.1.44 | drug target |
the enzyme is critically involved in the development of anaplastic thyroid carcinoma resistance to oxorubicin. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming |
760488 |
| 1.1.1.44 | drug target |
the enzyme might serve as promising therapeutic target for the treatment of cancers in which the enzyme (6PGD) is aberrantly overexpressed |
760658 |
| 1.1.1.44 | evolution |
phylogenetic analysis of cyanobacterial 6-phosphogluconate dehydrogenases (6PGDH) reveals that an amino acid residue at position 42 in Sy6PGDH is highly conserved for each order of cyanobacteria, but Synechocystis 6PGDH (Sy6PGDH) is phylogenetically unique. In Sy6PGDH, a single amino acid substitution at position 42 from serine to threonine enhances the affinity for NADP+ and alters the mode of inhibition by NADPH |
762131 |
| 1.1.1.44 | evolution |
phylogenetic analysis of cyanobacterial 6PGDHs reveales that the amino acid residue at position 42 in Sy6PGDH is highly conserved |
762131 |
